In this OncLive® My Treatment Approach program filmed at the 2026 ASCO Annual Meeting, Drs. Daniel Ahn and Midhun Malla examine the evolving first-line treatment landscape for metastatic pancreatic ductal adenocarcinoma. The discussion opens with how the FDA approval of NALIRIFOX has reshaped treatment selection and how clinicians differentiate it from FOLFIRINOX across mechanism of action, tolerability, and long-term survival outcomes from the NAPOLI 3 trial. Two patient cases ground the evidence in clinical reality, a 67-year-old male with KRAS G12D and liver metastases and a 54-year-old female with germline BRCA2 and KRAS G12V, exploring dose modification strategies, UGT1A1 considerations, performance status preservation, and molecularly informed sequencing. The program closes with a forward-looking discussion of the landmark RASolute 302 results for daraxonrasib presented at this meeting, the emerging KRAS-targeted sequencing story, and practical implementation guidance for community oncologists managing this challenging disease.
The first-line treatment landscape for metastatic pancreatic ductal adenocarcinoma (mPDAC) has evolved significantly, yet options remain limited for this challenging disease. This opening segment explores how performance status, age, frailty, molecular profiling, and patient preferences drive treatment selection.
Choosing between triplet and doublet regimens requires careful individualization based on performance status, comorbidities, and disease burden. This segment examines the clinical factors guiding selection between NALIRIFOX and FOLFIRINOX, including peripheral neuropathy risk, GI tolerability, and the role of genomic mutations in sensitizing tumors to platinum-based or DNA-damaging agents.
Translating clinical trial findings into everyday oncology practice requires nuanced judgment.
This segment centers on a 67-year-old male with ECOG PS 1 metastatic PDAC, a KRAS G12D mutation, elevated CA 19-9, and limited social support.
A 54-year-old female with pancreatic tail PDAC, bilateral nodules, a germline BRCA2 pathogenic variant, and a KRAS G12V somatic mutation presents a compelling case for molecularly informed treatment planning.
Maintaining patient functionality throughout long-term chemotherapy is one of the most critical and challenging goals in mPDAC management.
The final segment looks toward the future of mPDAC management, with a focus on the evolving role of KRAS inhibition across lines of therapy.
